Prof. Pier Paolo Piccaluga
School of Medicine, Bologna University, Italy
PI for Genomic and Precision Medicine Research Group
Pier Paolo Piccaluga, MD, Ph.D. is currently an Associate Professor of Pathology at the Department of Medical and Surgical Sciences, Bologna University School of Medicine— Institute of Hematology and Medical Oncology, and executive physician at The Biobank of Research, IRCCS Azienda Opedaliera-Universitaria di Bologna. In 2018, he was appointed to teaching posts at the Queen Mary University of London and Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. He is the author of several international publications in journals such as Nature Medicine, Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Clinical Oncology, Blood, Lancet Oncology, and Lancet Infectious Diseases. Prof. Dr. Piccaluga is ranked a Top Italian Scientist (TIS) by VIA-Academy.
Main clinical interest: Clinical Hematology, Hematopathology, and Molecular Diagnostics - Main Research Interests: viruses and lymphomagenesis; genomics and metabolomics of hematological malignancies; digital pathology
Prof. Liansheng Wang
Xiamen Univerisity, China
Wang Liansheng is currently a professor at the School of Information at Xiamen University, a dual-appointed professor at the Department of Gastroenterology at the School of Medicine, a doctoral supervisor, the deputy director of the Digital Fujian Health and Medical Big Data Research Institute, and the deputy leader of the AI group of the Radiology Branch of the Fujian Medical Association, Vice Chairman of MICS. He has been engaged in medical image processing research for a long time. He has hosted and participated in a number of scientific research projects, including the National Natural Science Foundation of China Instrument Project, the Ministry of Science and Technology’s Scientific and Technological Innovation 2030, the National Key R&D Project, the National Natural Science Foundation of China and Youth Projects, etc. His publications include Nature Machine Intelligence , Nature Communications, Cell Patterns, TMI, MedIA, CVPR/AAAI and other related research papers, and won the Tencent Rhinoceros Research Award, CSPE Young Investigator, the second prize of the Fujian Province Science and Technology Progress Award, and the 2023 Xiamen University Field Award The first prize of the Zhaowu Interdisciplinary Award, and led the team to win the championship in international medical imaging competitions 11 times.
Associate Professor Ahmed El-Hashash
Texas A &M University, America
Prof. Hashash has joined Texas A &M University as Associate Professor of Biomedicine. Prof. Hashash has several studies and publications on the genes/enzymes that control stem cell behavior and regenerative medicine. He has published more than 34 papers in reputed international journals and serving as an editorial board member of repute, in addition to over 17 book chapters. Prof. Hashash has received several international awards and recognitions over the years, including being the nominee for Kuwait Foundation for the Advancement of Science’s (KFAS) Prize in Applied Medical Sciences, and Manchester University Fellowship Award (UK). In, addiction, Prof. El-Hashash acts as a discussion leader at the prestigious Gordon Research Seminar/ Conference in USA, and a Peer Reviewer and International Extramural Review for The Medical Research Council (MRC) grant applications, London, UK. He is the editor or author of over 10 books on stem cell and regenerative medicine that have been published by the prestigious publisher Elsevier and Springer. Prof. Hashash is currently Book Series Editor at Elsevier publisher, USA (2019-2028).
Prof. Zhiyong Luo
Central South University, China
Dr. Zhiyong Luo is a professor and doctoral supervisor in the School of Life Sciences, Central South University (CSU). Dr. Luo is the director of the Cross-Center for New Drug Discovery of Central South University, and the leader of the " Major Disease Target Discovery and New Drug Development" in Biology at Central South University. His research interests include the discovery of new drugs for the treatment of tumors, metabolic steatohepatitis and fibrosis, psoriasis and genetic diseases, as well as the biosynthesis and synthetic biology of rare active ingredients in traditional Chinese medicine. He has presided over 10 top-level and international cooperation projects of National Natural Science Foundation of China, and 4 key projects of Hunan Provincial Natural Science Foundation and Science and Technology Research and Development Program. He has applied for 28 domestic and international invention patents, of which 26 patents have been authorized, and has published more than 70 papers in Nat Commun and other journals. He has discovered the world's first oncoprotein ASS1 activator-polyketide A derivative LM-2I, which is an original new drug candidate of anti-tumor class I with new structure, new target and new mechanism, and was authorized by the national invention patent and published by the international invention patent, which is the key core technology of our own; the research result was published in Nature Communications in April 2021, and has been published in both domestic and international markets. Besides the research results were published in Nature Communications in April, 2021, and have had a significant academic impact at home and abroad. In addition, he also developed ZLM-7, which targets tumor stem cells and angiogenesis, and ZSW, an anti-tumor quinone compound that targets STAT3; discovered NAC72 and MYB transcriptional regulators that transcriptionally activate dammarenediol synthase (DDS), a key enzyme in ginsenoside synthesis; and discovered and developed ginsenoside Rh2 derivatives, which are anti-tumor drugs that regulate the ERα/ERβ-TNFα pathway to induce apoptosis of tumor cells. Rh2 derivatives.
Prof. Fu WangXi’an Jiaotong University
Dr. Wang is currently a Professor of School of Basic Medical Sciences at Xi'an Jiaotong University. He has been selected as the Class A Young Top Talents of Xi'an Jiaotong University, the recipient of Shaanxi Provincial Outstanding Youth Scholars, the Chair Professor of the "Minjiang Scholars" of Fujian Province, and the editorial board of Asian Journal of Pharmaceutical Sciences、BMC Biology、BMC Cancer. Prof. Wang's main research interests include synthetic gene circuits and biomedical imaging. He has successively hosted more than 10 national and provincial level funds, including the National Natural Science Foundation of China (4 projects), the Ministry of Science and Technology Foreign Experts Program, the sub project of the National "973 Plan", the Shaanxi Provincial Natural Science Foundation of China (Programs for General, Key, and Outstanding Young Scholars), and the Shaanxi Provincial Science and Technology Activity Selection Funding Project for Returned Students (Excellent Category, 2 Projects). In recent years, as corresponding author, he has published more than 40 articles including Coordination Chemistry Reviews, Nuclear Acids Res., Mol Ther., Theranotics and Anal Chem among them. Moreover, he has applied /authorized more than 10 Chinese invention patents. He has won the first prize in Science and Technology in Shaanxi Province's high education institutions (2022, 2016) and the third prize in Science and Technology in Shaanxi Province (2017) as the first achievement person.
Speakers of ICBBE 2023
Prof. Aly El Sheikha, University of Ottawa, Canada
Prof. Yi-Tao Yu
University of Rochester/Medical Center/Department of Biochemistry and Biophysics, USA
A/Prof. Binh P. Nguyen
Victoria University of Wellington, New Zealand
A. Prof. Oleksiy V. Penkov
ZJU-UIUC Institute, Zhejiang University, China
Prof. Minxue Zheng
Suzhou Institute of Biomedical Engineering and Technology (SIBET)/Center for Nucleic Acid Diagnostic Technology